1984. Ceftriaxone–Sulbactam EDTA vs. Meropenem: Analysis of Failed Patients With Assessment of MIC Increases and Changes in Genotypic Profile in PLEA (a Phase 3, Randomized, Double-Blind Clinical Trial in Adults With Complicated Urinary Tract Infections or Acute Pyelonephritis)

Mohd Amin Mir, MS, MSc, PGDPM; Sarahah Chobhanary, BSc (Hons); Mandeep Chaudhary, PhD; Suhail Safdar, Ph.D; N.S. Patil, MD (Microbiology); Ruchi Girotra, DNB (Microbiology); Sahil Narang, MD (Pathology); Nazish Fatima, MD (Microbiology) and Other Principal Investigators; Venus Medicine Research Centre, Panchkula (Harayana), India, Venus Remedies Ltd., Panchkula (Harayana), India, Venus Hospital and Research Centre, Mumbai, India, Unipath Diagnostic, New Delhi, India, J.N.M.C1, Aligarh Muslim University, Aligarh (U.P), India

Session: 227. Clinical Trials
Saturday, October 6, 2018: 12:30 PM

Background. Ceftriaxone–sulbactam–EDTA (CSE) is a novel combination being developed to treat serious infections caused by Gram-negative bacteria. In vitro molecular biology studies have shown that the addition of EDTA in the combination helps to prevent horizontal gene transfer during conjugation by chelating the divalent manganese ion (Mg²⁺) required for the activity of DNA relaxases enzymes. An assessment of acquisition of resistant genes and a concomitant increase in MIC for patients that failed therapy in the Phase 3 clinical trial (NCT03477422) was conducted.

Methods. MICs were conducted on baseline and post-treatment isolates recovered during treatment period. MICs were determined using CLSI reference methods and MIC changes from baseline were further assessed. Bacterial DNA was extracted by the alkaline lysis method. β-Lactamase (BL) genes were amplified in single PCR using a panel of primers for detection of most β-lactamase enzymes, including extended-spectrum β-lactamase (ESBL) (blaTEM,blaSHV,blaCTX-M), b-lactamases (MBLs) (blaOXA,blaKPC,blaVIM,blaIM), carbapenemases (blaIMP,blaVIM,blaNDM), and class C cephalosporinases (blaOXA₁)

Results. Nine of 14 (64.3%) patients harbored four distinct BL genes (blaTEM₁,blaSHV₁,blaCTX-M₁,blaVIM₁) at baseline, and had acquired two additional genes (blaTEM₂,blaSHV₂) both carbapenemases (blaIMP₁,blaVIM₁) with MIC>8µg/mL for MR and 32-fold (1µg/mL to 32µg/mL) for CSE). No such increase in MIC or acquisition of resistant genes was noted in patients that failed therapy with CSE.

Conclusion. These findings highlight the need for an effective choice of empirical therapy as failed treatments could lead to selection for resistant genes, rendering once susceptible drug non-susceptible.

Disclosures. M. Chaudhary, Venus Medicine Research Centre: Employee, Salary. S. Chaudhary, Venus Medicine Research Centre: Employee and Shareholder, Salary. M. Chaudhary, Venus Medicine Research Centre: Board Member and Shareholder, Salary. A. Pyasi, Venus Medicine Research Centre: Employee, Salary. R. Girotra, Venus Medicine Research Centre: Employee, Salary.

1985. Atypical Symptoms and High Mortality Associated With Serogroup B Meningococcal Disease in Cartagena Colombia 2012–2016

Wilfrido Coronell-Rodríguez, PhD Tropical Medicine, Infectious disease Pedictricians, and Critical Care-Acute, Master of Epidemiology,1, 2 Puig, PhD, of Medicine, Universidad de Cartagena, Cartagena, Colombia, ‘Public Health, Universidad del Norte, Barranquilla, Colombia, ‘Professor Medicine Program, Corporacion Universitaria Rafael Núñez, Cartagena, Colombia

Session: 227. Clinical Trials
Saturday, October 6, 2018: 12:30 PM

Background. Meningococcal disease occurs in an endemic or epidemic form, such as meningitis or meningococcemia, the latter being a fast and high disease, mainly in children. Atypical symptoms have been described by the serogroup W. The aim of this study was to determine the clinical and epidemiological characteristics of invasive meningococcal disease (IMD) by serogroup B and the factors associated with mortality in pediatric patients, were identified for the study. Blood cultures were tested on both the Verigene® and AXDX platforms in tandem after flagging positive on the BACTEC® FX blood cultures were tested on the Bruker MALDI-TOF MS system for ID and VITEK®2 system (GN73 cards) for AST. Patient charts were then retrospectively evaluated to calculate time to active and optimal therapy. On comparing time to results (ID and AST) for AXDX with SOC, timing calculations to mimic setup and reporting times to final results and results were included.

Results. From time of blood culture positivity, mean time to ID averaged 36.3 hours for MALDI-TOF MS, 4.5 hours for the Verigene® system and 3.6 hours for AXDX, while the mean time to AST averaged 35.8 hours for the VITEK® 2 system and 8 hours for AXDX. Thirty-nine (45/141) patients were not on active therapy at time of positive blood culture. Of those 29 were put on active therapy within a mean of 21 hours (range: 9.3 hours to 5.6 days), such that 25% of patients could have been put on active therapy sooner had AXDX AST results been available clinically for action by a physician or stewardship team. Similarly, 34 were put on optimal therapy within a mean of 1.3 days (range: 9.3 hours to 5.6 days). Thus, 30% of patients could have had therapy optimized earlier had AXDX AST results been available.

Conclusion. Overall, the Accelerate Pheno® system is a reliable new diagnostic modality that has the potential to significantly reduce time to PBC ID and AST results, as well as lead to active and optimal therapy in children.

Disclosures. J. Schneider, Accelerate Diagnostics: Investigator, kits and data management and Research support.

1987. Validation of a MALDI-TOF MS-Based Direct-on-Target Microdroplet Growth Assay (DOT-MGA) for Rapid Detection of Extended-Spectrum β-Lactamase (ESBL)

Correa Caro-Martínez, MD; Ivgeny A. Medleiev, MD; Katrin Spargier, PhD; Mark Kostreva, PhD; and Karsten Becker, Prof. 1 Institute of Medical Microbiology, University Hospital Münster, Muenster, Germany, Bruker Daltonik, Bremen, Germany

Session: 228. Diagnostics: Bacteria and Mycobacteria
Saturday, October 6, 2018: 12:30 PM

Background. Most phenotypic methods routinely employed for the detection of ESBL and AmpC producing Enterobacteriaceae require 18 hours of incubation. Aiming to offer this clinically relevant information in a shorter time, we developed a MALDI-TOF MS-based direct-on-target microdroplet growth assay (DOT-MGA) as a one-step screening and confirmation panel in accordance with the EUCAST guidelines.

Methods. DOT-MGA was performed on 12 clinical Enterobacteriaceae strains displaying resistance against third-generation cephalosporins plus four control strains recommended by EUCAST for detection of ESBL production. Microdroplets (6 µL) containing bacterial suspension and antibiotics (cefepime, cefotaxime, ceftazidime, cefepime with or without clavulanic acid, and/or cefoxolin) in cation-adjusted Mueller-Hinton broth (CA-MHB) were spotted directly onto MBT Biotests 96 Microplates. Biotests were inoculated at 4 hours at 36°C in plastic transport boxes in order to avoid evaporation. Subsequently, culture medium was removed and MALDI-TOF MS of the cells adhered to the target's surface was performed. The minimum inhibitory concentration (MIC) was considered to be the lowest concentration at which the MALDI Biotyper software (Bruker) provided no specific identification. ESBL/AmpC production was defined as an 8-fold or greater decrease of
the cephalosporin MIC when combined with clavulanic acid and/or cefaclor, respectively. A computer-based algorithm was established to interpret the results, which were compared with those of broth microdilution (reference method). Resistance mechanisms of the clinical isolates were assessed by PCR.

Results. The method correctly identified the ESBL and AmpC production of both control and clinical strains (positive agreement, 100%; negative agreement, 100%), allowing the differentiation of each mechanism even in isolates displaying combined resistance. The results agreed with the characterization of the strains by PCR.

Conclusion. We present a rapid method for phenotypic detection of ESBL and AmpC that yields reliable results in a significantly shorter time, thus representing a potentially valuable tool in the routine detection of multidrug-resistant pathogens.

Disclosures. E. A. Idelevich, Bruker Daltonics: Co-inventor of a pending patent, Licensing agreement or royalty and Speaker honorarium. K. Sparbie, Bruker Daltonics: Employee, Salary. M. Kostreva, Bruker Daltonics: Employee, Salary. K. Becker, Bruker Daltonics: Co-inventor of a pending patent, Licensing agreement or royalty and Speaker honorarium.

1988 Development of a Laboratory Stewardship Algorithm for Anaplasma phagocytophilum Polymerase Chain Reaction Testing

Melis Anahat, MD, PhD; Vikram Pattanayak, MD, PhD; John Branda, MD; Marwan M. Azar, MD; Kc Coffey, MD, MPH; George Eng, MD, PhD; Joseph Rudolf, MD; Jason Baron, MD; Kent Lewandrowski, MD and Sarah Turbett, MD; Massachusetts General Hospital, Boston, Massachusetts; Yale University School of Medicine, New Haven, Connecticut; University of Minnesota Medical School, Minneapolis, Minnesota

Session: 228: Diagnostics: Bacteria and Mycobacteria Saturday, October 6, 2018: 12:30 PM

Background. Anaplasmosis often presents with fever and headache, and typical laboratory abnormalities include leucopenia and thrombocytopenia. Polymerase chain reaction (PCR) is the preferred diagnostic method. At our institution, laboratory abnormalities include leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) is the preferred diagnostic method. At our institution, PCR testing and decrease cost by 23%.

Methods. Part 1: Anaplasma PCR tests were included over a 3-year period. For each PCR result, white blood cell (WBC) and platelet (PLT) results from a sample collected near the time of PCR were evaluated in R Studio and GraphPad Prism. The significance of differences between PCR-positive and -negative cases was determined using the Mann–Whitney test. Cut-off values were chosen to maximize sensitivity of a screening algorithm for the detection of Anaplasma infection. Part 2: Mock stewardship was performed for 6 months. Screening criteria generated in phase 1 were applied to determine whether Anaplasma PCR would have been approved or rejected if stewardship were implemented based on laboratory and clinical parameters.

Results. Part 1: 2166 PCR tests were included. Patients with a positive Anaplasma PCR had lower median WBC and PLT counts than those with a negative result (Figure 1). Combining criteria of a WBC ≥ 11 K/µL and PLT ≥ 230.0 K/µL provided rejection criteria with 100% sensitivity and 25% specificity after excluding immunocompromised or unstable patients (Figure 2). Part 2: 663 PCR tests were analyzed. Of those, 155 (23%) met rejection criteria and were reviewed by committee. The committee mock refused 110 (71%) tests and mock accepted 49 (29%) based on clinical criteria. Of the patients with positive Anaplasma PCR, 1 met CBC rejection criteria and was mock refused by committee. On review, the patient was completing treatment for Anaplasmosis, indicating limited utility of testing. None of the 45 samples that were mock accepted by clinical stewardship were implemented based on laboratory and clinical parameters.

Conclusion. Implementation of a CBC-based stewardship algorithm would reduce unnecessary Anaplasma PCR testing and decrease cost by 23%.

Figure 1. Phase 1 differences in CBC laboratory values in patients with positive versus negative Anaplasma PCR test results. The shaded area represents the normal range, and the dotted horizontal line represents the threshold criteria. The open circles represent three immunocompromised or critically ill patients who tested positive for Anaplasma but had lab values above the thresholds.

Figure 2. Screening algorithm for Anaplasma PCR testing.

1989 Evaluation of Laser Light Scattering Technology in Rapid Diagnosis of Urinary Tract Infections in Children

Ferdaus Hassan, PhD; Heather Bushnell, BS; Connie Taggart, MLS (ASCP); Caitlin Gibbs, MLS (ASCP); Seven Hiraki, MLS (ASCP); Ashley Formanek, MLS (ASCP); Megan Gripi, MLS (ASCP); SM; and Ragunath Selvarangan, PhD; Children’s Mercy, Kansas City, Missouri; Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, Clinical Microbiology, Children’s Mercy Hospitals, Kansas City, Missouri, University of Minnesota Medical School, Minneapolis, Minnesota; Children’s Mercy Hospital-Kansas City, Kansas City, Missouri.

Session: 228: Diagnostics: Bacteria and Mycobacteria Saturday, October 6, 2018: 12:30 PM

Background. Urinalysis (UA) has been routinely used as a screening tool prior to microbial culture set-up in many laboratories. BacterioScan 216Dx instrument utilizes laser light scattering technology to detect bacterial growth in urine and results are available in 3 hours. The aim of this study was to compare the performance of 216 Dx and UA against culture as gold standard.

Methods. Clean-catch, unpreserved, either UA positive (leukocyte esterase > trace, or nitrite positive or white blood cells >5/hpt) or UA negative samples from children aged ≤18 years were tested by 216Dx within 24 hours of sample collection. "Likely positive" samples by 216Dx were tested by MALDI-TOF for direct bacterial identification. Sensitivity and specificity of 216Dx and UA was determined against urine culture.

Results. Total of 205 urine samples were included in this study, of which 48.0% (98/205) and 52.0% (107/205) were UA positive and negative, respectively. Overall sensitivity, specificity, positive and negative predictive value (PPV and NPV) of 216Dx and UA are shown in table below. Of 27 true positive (TP) samples by 216Dx, 77.0% (21/27) were successfully identified by MALDI-TOF. There were a total of 96 samples identified as contamination/normal flora by culture. Among these, 63 samples (65.0%) were detected as true negative (TN) by 216Dx vs. 50 samples (53.1%) as TN by UA. Two false negative (FN) samples by 216Dx and one FN by UA were K. oxytoca, S. epidermidis (both >100 K cfu/mL) and E. coli (>100 K cfu/mL), respectively.

Conclusion. Although sensitivity of both 216Dx and UA is comparable, specificity of 216Dx was higher than UA. Also, 216Dx showed better performance in detecting urine contamination, thus reducing laboratory reagent and labor cost. Faster turn-around-time of 216Dx coupled with rapid identification of uropathogen by MALDI-TOF has the potential to reduce unnecessary antibiotic use, improve patient management and reduce overall healthcare-related cost.

| Assay   | TP | FP | TN | FN | % Sensitivity (95% CI) | % Specificity (95% CI) | % PPV (95% CI) | % NPV (95% CI) |
|---------|----|----|----|----|------------------------|------------------------|-----------------|----------------|
| 216Dx  | 27 | 36 | 140 | 2 | 91.1 (75.7–98.6)        | 79.5 (72.6–85.1)        | 42.8 (30.6–55.9) | 96.6 (84.4–99.7) |
| UA     | 28 | 70 | 106 | 1 | 95.5 (80.3–99.6)        | 60.2 (52.5–67.4)        | 28.5 (21.1–36.7) | 99.6 (94.1–99.8) |

Disclosures. All authors: No reported disclosures.